Today: 23 April 2026
Subscribe
Browse Category

NASDAQ:NDRA 13 October 2025

Biotech Meets Crypto: ENDRA Life Sciences (NDRA) Stock Skyrockets 33% — Analyst Target $50

Biotech Meets Crypto: ENDRA Life Sciences (NDRA) Stock Skyrockets 33% — Analyst Target $50

ENDRA Life Sciences shares surged 33% to $8.63 midday Oct. 13, 2025, after announcing a $4.9 million crypto-asset treasury placement managed by Arca. The company’s main TAEUS imaging product targets liver fat measurement, with a 250-patient FDA trial underway. Q2 net loss narrowed to $1.2 million, with cash at $1.8 million as of June 30. Analyst coverage is limited; the 12-month price target stands at $50.
13 October 2025
·

Stock Market Today

  • Jim Cramer Eyes More Procter & Gamble Shares If Price Dips Below $140
    April 23, 2026, 1:10 PM EDT. On Thursday, Jim Cramer highlighted a market rotation from software to hardware as ServiceNow shares fell 17% post-earnings despite beating forecasts. Chip designer Arm led the hardware rally, surging 6% to record highs, though Cramer expressed concern over its CEO's expanded role at SoftBank. Investor attention turns to Procter & Gamble, which rose over 1% ahead of Friday's earnings. Cramer said he plans to "buy more" shares if the price falls below $140, praising new CEO Shailesh Jejurikar's international expertise. Analysts expect modest earnings per share growth near 1% and organic revenue growth below 2%, with eyes on cost pressures from higher resin prices, a packaging material derived from oil.

Latest article

IREN Stock Jumps as AI Cloud Bet Meets $6 Billion Dilution Test

IREN Stock Jumps as AI Cloud Bet Meets $6 Billion Dilution Test

23 April 2026
IREN shares jumped 7.3% to $51.94 in New York Thursday amid debate over its shift from bitcoin mining to AI cloud services. The company plans to deploy 150,000 Nvidia GPUs by late 2026 and reported $2.8 billion in cash as of January. AI cloud revenue remains small compared to bitcoin mining, with $17.3 million last quarter. IREN can sell up to $6 billion in stock under a new SEC filing.
Hims Adds Lilly’s Zepbound and Foundayo as GLP-1 Price Fight Moves Online

Hims Adds Lilly’s Zepbound and Foundayo as GLP-1 Price Fight Moves Online

23 April 2026
Hims & Hers Health said Thursday its providers can now send prescriptions for Eli Lilly’s Zepbound and Foundayo to LillyDirect, expanding branded obesity drug options on its platform. The move follows a similar deal with Novo Nordisk in March. Hims listed Foundayo from $149 a month and Zepbound from $299. The company previously stopped advertising compounded GLP-1s amid tighter U.S. regulations.
Warren Buffett Successor Greg Abel Tightens Grip on Berkshire Hathaway Portfolio, Pushes New Money Into Japan

Warren Buffett Successor Greg Abel Tightens Grip on Berkshire Hathaway Portfolio, Pushes New Money Into Japan

23 April 2026
Greg Abel now controls about 94% of Berkshire Hathaway’s $300 billion stock portfolio after Todd Combs’ departure, consolidating authority more than Warren Buffett had planned. Abel has kept major U.S. holdings largely intact but increased investments in Japanese firms, including a new $1.8 billion stake in Tokio Marine. Recent portfolio trims, such as Apple and Amazon, reflect Buffett’s last quarter in charge.
Go toTop